Clinical Trials
11 trialsActive not recruiting × decitabine and cedazuridine drug combination × Other hematologic neoplasm × Clear all
NCT03613532 2026-05-20
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT04975919 2026-05-14
Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05600894 2026-05-13
Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05396859 2026-04-27
Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia
OHSU Knight Cancer Institute
Phase 1 Active not recruiting
NCT04980404 2026-03-30
Inqovi Maintenance Therapy in Myeloid Neoplasms
Massachusetts General Hospital
Phase 1 Active not recruiting
NCT04746235 2026-03-12
Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04655755 2026-02-18
Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT05201066 2026-01-07
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
Novartis
Phase 2 Active not recruiting
NCT04657081 2025-12-08
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)
Taiho Oncology, Inc.
Phase 1/2 Active not recruiting
NCT04817241 2025-11-10
Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT05883956 2025-03-20
PREFER-HMA
Otsuka Australia Pharmaceutical Pty Ltd
Phase 3 Active not recruiting